Robert MD - Sensei Biotherapeutics Chief Officer
| SNSE Stock | USD 0.54 0.02 3.57% |
Insider
Robert MD is Chief Officer of Sensei Biotherapeutics
| Age | 58 |
| Address | 1405 Research Boulevard, Rockville, MD, United States, 20850 |
| Phone | 240 243 8000 |
| Web | https://www.senseibio.com |
Sensei Biotherapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2703) % which means that it has lost $0.2703 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4517) %, meaning that it created substantial loss on money invested by shareholders. Sensei Biotherapeutics' management efficiency ratios could be used to measure how well Sensei Biotherapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of December 1, 2024, Return On Tangible Assets is expected to decline to -0.48. The current year's Return On Capital Employed is expected to grow to -0.51. At present, Sensei Biotherapeutics' Non Currrent Assets Other are projected to decrease significantly based on the last few years of reporting.Similar Executives
| Showing other executives | INSIDER Age | ||
| Mark Lappe | Inhibrx | 57 | |
| Paul Manley | Tff Pharmaceuticals | N/A | |
| Susan MS | Eliem Therapeutics | N/A | |
| Jo PalmerPhillips | Eliem Therapeutics | N/A | |
| Christopher Cano | Tff Pharmaceuticals | 53 | |
| Dale Christensen | Tff Pharmaceuticals | N/A | |
| Harlan Weisman | Tff Pharmaceuticals | 72 | |
| Robert MBA | Eliem Therapeutics | 56 | |
| Erin Lavelle | Eliem Therapeutics | 47 | |
| Glenn Mattes | Tff Pharmaceuticals | 67 | |
| Kirk Coleman | Tff Pharmaceuticals | 50 | |
| Quinn Deveraux | Inhibrx | N/A | |
| James JD | Eliem Therapeutics | 58 | |
| Anthony Hickey | Tff Pharmaceuticals | N/A | |
| MBA MD | Eliem Therapeutics | 63 | |
| BS CPA | Inhibrx | 42 | |
Management Performance
| Return On Equity | -0.45 | ||||
| Return On Asset | -0.27 |
Sensei Biotherapeutics Leadership Team
Elected by the shareholders, the Sensei Biotherapeutics' board of directors comprises two types of representatives: Sensei Biotherapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sensei. The board's role is to monitor Sensei Biotherapeutics' management team and ensure that shareholders' interests are well served. Sensei Biotherapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sensei Biotherapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Edward Horst, Chief Officer | ||
| Christopher JD, VP Counsel | ||
| Elisabeth Colunio, VP HR | ||
| Lora Pike, Vice Communications | ||
| Steven Fuller, Chief Officer | ||
| Robert MD, Chief Officer | ||
| Erin Colgan, Chief Officer | ||
| MS MBA, Chief Officer | ||
| Josiah Craver, Principal Finance | ||
| John MBA, CEO President | ||
| MPH MBA, Chief Officer | ||
| MBA MBA, CEO Pres | ||
| FACP MD, Chief Officer |
Sensei Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sensei Biotherapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.45 | ||||
| Return On Asset | -0.27 | ||||
| Current Valuation | (28.92 M) | ||||
| Shares Outstanding | 25.15 M | ||||
| Shares Owned By Insiders | 34.39 % | ||||
| Shares Owned By Institutions | 8.81 % | ||||
| Number Of Shares Shorted | 200.26 K | ||||
| Price To Book | 0.30 X | ||||
| EBITDA | (33.39 M) | ||||
| Net Income | (34.1 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Sensei Biotherapeutics is a strong investment it is important to analyze Sensei Biotherapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Sensei Biotherapeutics' future performance. For an informed investment choice regarding Sensei Stock, refer to the following important reports:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sensei Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade Sensei Stock refer to our How to Trade Sensei Stock guide.You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sensei Biotherapeutics. If investors know Sensei will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sensei Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.19) | Return On Assets (0.27) | Return On Equity (0.45) |
The market value of Sensei Biotherapeutics is measured differently than its book value, which is the value of Sensei that is recorded on the company's balance sheet. Investors also form their own opinion of Sensei Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sensei Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sensei Biotherapeutics' market value can be influenced by many factors that don't directly affect Sensei Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sensei Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sensei Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sensei Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.